The mission details of the funder are not explicitly provided in the given description.
The ADDF-Harrington Scholar Program focuses on turning academic research and discoveries into medications for Alzheimer’s disease and related dementias. It provides up to $600,000 per year over several years, alongside project support from pharmaceutical experts. This program emphasizes funding for projects targeting a range of therapeutic areas such as proteostasis, senescence, epigenetics, vascular pathology, neuroprotection, and various biological processes crucial for brain health. It encourages proposals for novel targets that have a potential impact on dementia therapy, except for anti-amyloid approaches and cholinesterase inhibitors, while showing a preference for approaches that differentiate from existing tau-targeted therapies.